RNA model flags resistance signals in blood from BRAF V600E colorectal cancer
A study from UT MD Anderson and Eigen Bio found that an RNA foundation model could identify treatment-response biology and possible resistance mechanisms from longitudinal blood samples in MSS, BRAF V600E metastatic colorectal cancer. The work, to be presented at ESMO 2026, points to serial blood RNA as a non-invasive way to study why patients with the same mutation respond differently to therapy.
Why it matters: - Longitudinal blood RNA may help explain why patients with the same BRAF V600E colorectal cancer mutation respond differently to treatment. - The findings suggest liquid biopsy could do more than monitor response. It may also surface biology that points to resistance and new drug targets. - The study is hypothesis-generating, so the results still need validation in larger independent cohorts.
What happened: - Researchers from The University of Texas MD Anderson and Eigen Bio analyzed paired pretreatment and on-treatment extracellular vesicle RNA, or evRNA, from patients with microsatellite-stable, BRAF V600E metastatic colorectal cancer. - The work will be presented at the European Society for Medical Oncology Congress 2026. - The team used Eigen-1, Eigen Bio’s RNA foundation model, to search the blood RNA data without using clinical response labels or predefined response signatures. - After the model identified transcriptional states, researchers compared those states with RECIST-defined outcomes.
The details: - The model independently recovered response-associated biology that had been identified in earlier work. - The transcriptional states identified without response labels showed 81% post-hoc concordance with RECIST-defined clinical response. - The model also mapped the newly identified states onto mechanistic networks and surfaced additional programs linked to treatment resistance. - Those resistance-linked programs generated hypotheses about how some tumors may escape therapy and where future strategies could intervene. - The data came from an earlier study of encorafenib, cetuximab and nivolumab in previously treated patients with MSS, BRAF V600E metastatic colorectal cancer. - That earlier study had shown a 50% objective response rate in a single-institution phase 1/2 setting.
Between the lines: - The new analysis builds on a broader question in BRAF V600E colorectal cancer: the same mutation does not guarantee the same biology or the same treatment outcome. - The randomized phase II SWOG S2107 trial found that adding nivolumab to encorafenib and cetuximab did not improve progression-free or overall survival across the study population. - That result underscores the biologic heterogeneity that can persist even within a molecularly defined cancer subtype. - The study suggests serial evRNA may capture treatment-linked biology that is invisible in a single baseline sample.
What's next: - Researchers plan to test whether the same biological states recur in larger cohorts and across other treatment settings. - Future studies will need to validate whether the resistance mechanisms suggested by the model translate into clinically useful targets. - If confirmed, the approach could support a new use for longitudinal liquid biopsy: learning from response to guide future therapy development.
The bottom line: - A blood-based RNA model found response-linked biology and candidate resistance mechanisms in BRAF V600E colorectal cancer without being told which patients responded.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Austin Daily Sun
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.